跳至主要内容
临床试验/CTRI/2022/07/043774
CTRI/2022/07/043774已完成2 期

A randomized placebo controlled clinical trial to determine the efficacy of amaranthus extract on male pattern hair loss

Arjuna Natural Pvt Ltd0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Males 25 to 45 years of age with clinically diagnosed male pattern hair loss (MPHL) measured with Trichoscan.
  • Willing to maintain the same hairstyle, hair length, and hair color during the entire study and refrain from cutting the scalp hair.
  • Subjects willing to give written informed consent.

排除标准

  • History of active hair loss due to alopecia areata, scarring alopecia, diffuse telogen effluvium or conditions other than androgenic alopecia.
  • Any dermatological disorders of the scalp which might interfere with the application of Investigational Medical Product or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis or scalp atrophy or psychiatric disorder including trichotillomania.
  • Subjects who have received radiation to the scalp, cancer treatment in the 6 months prior to start of the study or have a plan to do treatments during study.
  • Evidence of hypogonadism defined as serum testosterone less than 250ng.
  • Subjects who have had hair transplant or undergoing any medical treatments.
  • Topical minoxidil, finasteride, phenytoin, 5 alpha reductase inhibitors, isotretinoin, or any other OTC, prescription medication topical or oral herbal supplement for hair growth or medications known to promote hair loss within the past 3 months.
  • Current or within 2 weeks prior to first dosing use of vasodilating (e.g. Pentoxifylline, nitroglycerine), anticoagulating, immunosuppressive or corticosteroid drugs.
  • Positive HIV-Antibody, HBs-Antigen or HCV-Antibody-Test, STDs like Syphilis, autoimmune disorders, Diabetes mellitus, Coagulation or iron deficiencies, hypothyroidism or hyperthyroidism.

研究者

相似试验